Stocktoria
Theravance Biopharma, Inc. TBPH
Theravance Biopharma, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $107.5M | $64.4M | $57.4M | $51.3M | $55.3M | $71.9M | $73.4M | $60.4M | $15.4M | $48.6M |
| R&D expense | $37.4M | $37.6M | $40.6M | $63.4M | $193.7M | $261.0M | $219.2M | $201.3M | $173.9M | $141.7M |
| SG&A expense | $73.7M | $69.2M | $70.1M | $67.1M | $99.3M | $108.5M | $106.1M | $97.1M | $95.6M | $84.5M |
| Operating income | -$3.6M | -$46.9M | -$56.0M | -$92.0M | -$257.8M | -$297.6M | -$251.9M | -$238.8M | -$260.1M | -$180.5M |
| Interest expense | — | — | $2.4M | $6.4M | $8.5M | $8.5M | $31.9M | $10.5M | $8.5M | $1.4M |
| Income tax | $23.4M | $11.8M | $5.9M | $9,000 | -$151,000 | -$8.5M | -$5.2M | -$10.6M | $13.7M | $10.1M |
| Net income | $105.9M | -$56.4M | -$55.2M | $872.1M | -$199.4M | -$278.0M | -$236.5M | -$215.5M | -$285.4M | -$190.7M |
| EPS (diluted) | $2.06 | $-1.15 | $-1.00 | $11.85 | $-2.87 | $-4.46 | $-4.25 | — | — | — |
| Operating cash flow | $238.5M | -$11.5M | -$27.0M | -$187.0M | -$235.8M | -$262.7M | -$238.2M | -$112.9M | -$201.1M | -$99.0M |
| Free cash flow | — | — | — | — | — | — | — | — | — | -$101.1M |
| Cash & equivalents | $167.8M | $37.8M | $39.5M | $298.2M | $90.0M | $81.5M | $58.1M | $378.0M | $89.0M | $344.7M |
| Inventory | — | — | — | — | — | — | — | $0 | $16.8M | $12.2M |
| Total assets | $485.6M | $354.2M | $382.0M | $607.4M | $374.8M | $469.1M | $408.8M | $560.2M | $441.4M | $639.3M |
| Shareholders' equity | $296.7M | $175.5M | $213.0M | $441.8M | -$338.6M | -$303.8M | -$223.8M | -$51.6M | $115.2M | $350.2M |
Growth · year-over-year · Revenue CAGR 9.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +66.9% | +12.1% | +11.8% | -7.2% | -23.0% | -2.1% | +21.6% | +292.4% | -68.4% | +15.5% |
| Net income growth | — | — | -106.3% | — | — | — | — | — | — | — |
| EPS growth | — | — | -108.4% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.